The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: Results of a phase 2, open-label study

Melanoma Research

Volumn 21, Issue 1, 2011, Pages 80-83

  Imhof, Laurence ^a   Goldinger, Simone M ^a   Baumann, Katrin ^a   Schad, Karin ^a   French, Lars E ^a   Röthlisberger, Peter ^b   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Geistlich Pharma AG   (Switzerland)

Author keywords

Antibacterial agent taurolidine; Highly advanced melanoma; Second third line treatment

Indexed keywords

TAUROLIDINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; TAURINE; THIADIAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NOSE CAVITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TAURINE; THIADIAZINES; TREATMENT OUTCOME;

EID: 79952769968     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328341442d     Document Type: Article

References (33)

1. Neary MN, Hallihan P, Wang JH, Pfirrmann RW, Bouchier-Hayes DJ, Redmond HP. The evolving role of taurolidine in cancer therapy. Ann Surg Oncol 2010; 17:1135-1143.
2. Shrayer DP, Lukoff H, King T, Calabresi P. The effect of taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 2003; 14:295-303. (Pubitemid 36583815)
3. Da Costa ML, Redmond HP, Bouchier-Hayes DJ. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. J Surg Res 2001; 101:111-119. (Pubitemid 34044548)
4. Jacobi CA. Taurolidine in cancer treatment - presentation of a new therapy concept (In German). Bremen: UNI-MED Verlag AG; 2003.
5. Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61:6816-6821. (Pubitemid 32896506)
6. Jacobi CA. Taurolidin in der Chirurgie. Aktueller Stand der Behandlung von Tumorerkrankungen, Teil 1 und Teil 2. CHAZ 2003; Jg. 4; Heft 10: 407-410 (Teil 1),
7. Heft 11 + 12: 477-481 (Teil 2).
8. Jacobi CA, Braumann C. Der Einsatz von Taurolidin in der Tumor-Chirurgie. Wehrmedizin und Wehrpharmazie; Jg. 28, 02/2004.
9. Petrovic L, Schlegel KA, Ries J, Park J, Diebel E, Schultze-Mosgau S, et al. In-vitro-effect of taurolidine on squamous cell carcinoma of the oral cavity. Oral Maxillofac Surg 2003; 7:102-107.
10. Pross M, Nestler G, Kuhn R, Krüger S, Lippert H. Reduced tumor growth due to taurolidine [In German]. CHAZ 2 2001; 11/12:459-465.
11. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M. The effect of taurolidine on brain tumor cells. Anticancer Res 2002; 22:809-814. (Pubitemid 34475233)
12. Stendel R, Stoltenburg-Didinger G, Brock M. Taurolidine - underestimated antineoplastic effect? J Cancer Res Clin Oncol 2002; 128:140.
13. Stendel R, Stoltenburg-Didinger G, Brock M. Apoptotic changes in brain tumor cells induced by taurolidine. J Cancer Res Clin Oncol 2002; 128:150.
14. Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Möhler H. Enhancement of fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res 2003; 23:2309-2314. (Pubitemid 36897096)
15. Stendel R, Scheurer L, Schlatterer K, Gminski R, Möhler H. Taurolidine-fibrin-sealant-matrix using spray application for local treatment of brain tumors. Anticancer Res 2004; 24:631-638. (Pubitemid 38625000)
16. Stendel R, Brock M. Therapy of malignant glioma with taurolidine - Experimental research and clinical application. In: Jacobi CA, editor. Taurolidine in the treatment of carcinoma - presentation of a new therapy concept. Bremen: Uni-Med Verlag; 2003. pp. 60-66.
17. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper Ch, Jänisch W, et al. Treatment of glioblastoma with intravenous taurolidine: first clinical experience. Anticancer Res 2004; 24:1143-1148.
18. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, et al. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma - a mouse model. J Surg Res 2007; 143:372-378. (Pubitemid 350101573)
19. Stendel R, Biefer HR, Dékany GM, Kubota H, Münz C, Wang S, et al. The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy 2009; 5:194-210.
20. Rodak R, Kubota H, Ishihara H, Eugster H P, Könü D, Möhler H, et al. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 2005; 102:1055-1068. (Pubitemid 43193975)
21. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009; 335:261-269.
22. Braumann C, Tangermann J, Jacobi C, Mueller J, Dubiel W. Novel anti-angiogenic compounds for application in tumor therapy-COP9 signalosome-associated kinases as possible targets. Mini Rev Med Chem 2008; 8:421.
23. Möhler T, Willhauck-Fleckenstein M, Schwartz-Albiez R, Merling A, Möhler H. Inhibition of endothelial cell adhesion and in vitro angiogenesis by Taurolidine. Cancer Therapy 2008; 6:623-628.
24. Daigeler A, Chromik A, Geisler A, Bulut D, Hilgert Ch, Krieg A, et al. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol 2008; 32:1205.
25. Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert Ch, Lehnhardt M, et al. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res 2008; 27:82.
26. Little D, Regan M, Bouchier-Hayes D. Perioperative immune modulation. Surgery 1993; 114:87-91. (Pubitemid 23209347)
27. Walters D, Muff R, Langsam B, Gruber P, Born W, Fuchs B. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs 2007; 25:305-312. (Pubitemid 46944855)
28. Reith H, Dittrich H, Haarmann W, Smektala R, Dohle J, Kozuschek W. Adjuvant therapy of peritonitis and its septical manifestations with taurolidine - a prospective randomised study (In German). Chir Gastroenterol 1996; 12:358-362.
29. O'Brien GC, Cahill RA, Bouchier-Hayes DJ, Redmond HP. Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sc 2006; 175:10-14.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
31. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10. (Pubitemid 19099520)
32. Legha SS. Treatment of brain metastases from melanoma. J Clin Oncol 2005; 23:3155-3156.
33. Mc Court M, Wang JH, Sookhai S, Redmond P. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000; 7:685-691.